NCT06793839 3D Contrast Enhanced Acoustic Perfusion Imaging in Adult After Subarachnoid Hemorrhage
| NCT ID | NCT06793839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Caen |
| Condition | Subarachnoid Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2025-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-05-01 with a primary completion date of 2025-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, with three major complications : early brain injury (EBI), vasospasm and delayed cerebral ischemia (DCI). Those patients are often given care in neurocritical care. Imaging is particularly useful to diagnose these complications. Brain imaging includes CT scan, MRI and arteriography which are not easily available and need an intrahospital transportation. Furthermore, intrahospital transportation of critically ill patients is associated with significant complications Here, investigators try to show that a new non-invasive bedside device, based on 3D enhanced ultrasonography, is able to detect principal arteries of anterior circulation of the brain.
Eligibility Criteria
Inclusion Criteria: * Admitted in neurologic ICU of the CHU Caen, Normandy, for a subarachnoid hemorrhage of the anterior circulation. * Usable ultrasound temporal window. * 18 years old and more. * Consent of the participant or the trusted person. Exclusion Criteria: * non-aneurysmal subarachnoid haemorrhage. * Contraindication to ultrasound contrast agent Sonovue, including allergies to a compound. * Uncontrolled systemic hypertension. * Acute respiratory distress syndrome. * Pregnancy or breastfeeding mother. * Vulnerable person with guardianship or curatorship. * Patient not affiliated to french social security system (Sécurité Sociale)
Contact & Investigator
Clément GAKUBA, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Caen
Frequently Asked Questions
Who can join the NCT06793839 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Subarachnoid Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06793839 currently recruiting?
Yes, NCT06793839 is actively recruiting participants. Contact the research team at gakuba-c@chu-caen.fr for enrollment information.
Where is the NCT06793839 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT06793839 clinical trial?
NCT06793839 is sponsored by University Hospital, Caen. The principal investigator is Clément GAKUBA, PhD at University Hospital, Caen. The trial plans to enroll 15 participants.